Patient with multiple myeloma and suspected cardiac amyloidosis (RCD code: III‑3A.2a)
49 year‑old patient with multiple myeloma diagnosed a year earlier, after a few cycles of chemotherapy was admitted to hospital with heart failure symptoms accompanied by a rapid atrial flutter. Echocardiography revealed eccentric hypertrophy of the left ventricle and reduced ejection fraction approx. 20% and non sustained ventricular tachycardia episodes in the Holter ECG. Due to the gradually deteriorating patient’s condition electrical cardioversion was performed restoring sinus rhythm. Applied pharmacological treatment brought relief of symptoms reported at admission. To clarify the etiology of heart failure coronary angiography was performed excluding the presence of coronary artery disease. Because of the frequent occurrence of amyloidosis in patients with multiple myeloma, the amyloid cardiomyopathy was suspected and the investigation in that direction was started. Histology samples of abdominal fat and gums mucous in a hematoxylin and eosin and Sirius red staining showed no signs of amyloidosis. However, bone marrow biopsy revealed the presence of protein corresponding to the extracellular amyloid deposits. The patient died a few months later in hematology clinic due to severe multiple organ failure associated with generalized amyloidosis. JRCD 2015; 2 (2): 22–25
Merlini G, Bellotti V,: Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583–596.
Mothy D, Damy T, Cosandy P, et al. Cardiac amyloidosis: Updates in diagnosis and management. Archives of Cardiovascular Disease 2013; 106: 528–540.
Brandt LE, Morie AG. Current trends in diagnosis and management of cardiac amyloidosis. Curr Probl Cardiol 2013; 38: 53–96.
Banypersad SM, Moon JC, Whelan C, et al. Updates in Cardiac Amyloidosis:
A Review. J Am Heart Assoc. 2012; 1: e000 364.
Pattanshetty DJ, Bhat PK, Chamberlain WA, et al. Isolated cardiac involvement in primary amyloidosis. Tex Heart Inst J 2013; 40: 615–618.
Falk RH, Quarta CC, Dorbala S. How to Image Cardiac Amyloidosis. Circ Cardiovasc Imaging 2014; 7: 552–562.
Siquera‑Filho AG, Cunha C, Tajik AJ, et al. M‑mode and two‑dimensional echocardiographic features in cardiac amyloidosis. Circulation 1981; 63: 188–196.
Xia R, Gao F, Sun J, et al. Cardiac magnetic resonance imaging of systemic amyloidosis patients with normal left ventricular ejection fraction: An initial study. Pak J Med Sci 2013; 29: 1300–1305.
Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis. Noninvasive Imaging Compared to Endomyocardial Biopsy. J Am Coll Cardiol 2008; 51: 1022–1030.
Quarta C, Kruger JL, Falk RH. Cardiac Amyloidosis. Circulation 2012; 126: e178–e182.
Dubrey SW, Cha K, Anderson J. The clinical features of immunoglobulin light‑chain (AL) amyloidosis with heart involvement. Q J Med 1998; 91: 141–157.
Libbey CA, Skinner M, Cohen AS. Use of Abdominal Fat Tissue Aspirate in the Diagnosis of Systemic Amyloidosis. Arch Intern Med. 1983; 143: 1549–1552.
Masouyé I. Diagnostic screening of systemic amyloidosis by abdominal fat aspiration: an analysis of 100 cases. American Journal of Dermatopathology: February 1997; 19: 41–45.
Bogov B, Lubomirova M, Kiperova B. Biopsy of subcutaneus fatty tissue for diagnosis of systemic amyloidosis. Hippokratia 2008; 12: 236–239.
Janin A, Flipo RM, et al. Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis: A prospective clinical and immunohistologic study in 59 patients. Arthritis and Rheumatism 1993; 36: 691–697.
Stoopler ET, Sollectio TP, Sow‑Yeh Chen. Amyloid deposition in the oral cavity: A retrospective study and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol 2003; 95: 674–680.
Packer DL, Bardy GH, Worley JS, et al. Tachycardia‑induced cardiomyopathy:
A reversible form of left ventricular dysfunction. The American Journal of Cardiology 1986; 57: 563–570.
Shinbane J, Wood MA, Jensen N, et al. Tachycardia‑Induced Cardiomyopathy: A Review of Animal Models and Clinical Studies. J Am Coll Cardiol. 1997; 29: 709–715.
Gottdiener JS, Appelbaum FR, Ferrans VJ. Cardiotoxicity Associated With High‑Dose Cyclophosphamide Therapy. Arch Intern Med. 1981; 141: 758–763.
Dhesi S, Chu MP, Blevins G, et al. Cyclophosphamide‑Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management. Journal of Investigative Medicine High Impact Case Reports January‑March 2013: 1–7.
Chakraborty R, Mukkamalla S, Calderon N. Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature. BJMP 2013; 6: a631.
Bockorny M, Chakravarty S, Schulman P, et al. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: A case report and review of the literature. Acta Haematologica 2012; 128: 244–247.
Patel KS, Hawkins PN, Whelan CJ, et al. Life‑saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis. BMJ Case Reports 2014; 206: 600.
Mori M, Kitagawa T, Sasaki Y, et al. Long‑term survival of a patient with multiple myeloma‑associated severe cardiac AL amyloidosis after implantation of a cardioverter‑defibrillator. The Japanese journal of clinical hematology 2014; 55: 450–455.
Lin G, Dispenzieri A, Kyle R, et al. Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis. J Cardiovasc Electrophysiol 2013; 24: 793–798.
- There are currently no refbacks.